D e s i g n
Randomized {allocation concealed*} †, unblinded,* controlled trial with 5-week follow-up.
S e t t i n g
Ambulatory internal medicine clinics of 2 university-affiliated hospitals in Canton, Ohio, USA.
P a t i e n t s
160 patients ≥ 18 years of age (mean age 50 y, 57% women) with dyspepsia and H. pylori infection who had a Glasgow Dyspepsia Severity Score (GDSS) of ≥ 3 (score range 0 to 20) and a positive carbon 14 urea breath test result. Exclusion criteria included previous treatment of H. pylori infection, pregnancy, personal or family history of gastrointestinal malignancy, antibiotic therapy in the previous 6 weeks, previous gastric surgery, and hepatic insufficiency. Follow-up was 94%.
I n t e r v e n t i o n 80 patients were allocated to a 1-day regimen of 2 tablets of bismuth subsalicylate, 262 mg each tablet, 4 times; 1 tablet of metronidazole, 500 mg, 4 times; amoxicillin suspension, 2 g, 4 times; and 2 tablets of lansoprazole, 30 mg each tablet, once (1-d regimen group). 80 patients were allocated to a 7-day regimen of 1 tablet of clarithromycin, 500 mg, twice daily; 2 tablets of amoxicillin, 500 mg each tablet, twice daily; and 1 tablet of lansoprazole, 30 mg, twice daily (7-d regimen group).
M a i n o u t c o m e m e a s u r e s
Eradication rates of H. pylori, changes in GDSS score, and adverse effects.
M a i n r e s u l t s
All patients remained on their assigned treatment. 1-day therapy was not inferior to 7-day therapy for rates of eradication of H. pylori (Table) . The mean baseline GDSS score was 11 (standard deviation [SD] 3.4) in the 1-day regimen group and 10 (SD 3.3) in the 7-day regimen group. The groups did not differ for mean change from baseline in GDSS scores (both groups had a mean decrease from baseline of 7.5). None of the patients in either group reported intolerance to their treatment, and rates of side effects did not differ between groups.
C o n c l u s i o n
In patients with dyspepsia, a 1-day quadruple therapy regimen was not inferior to a 7-day triple therapy regimen for eradication of Helicobacter pylori infection. 
1-day quadruple therapy was not inferior to 7-day triple therapy for eradication of Helicobacter pylori infection in dyspepsia

C o m m e n t a r y
Dyspepsia is endemic and chronic. Most patients who are evaluated are diagnosed with nonulcer, or functional, dyspepsia. Systematic reviews support a modest benefit of H. pylori eradication in such patients, with perhaps 1 cure for every 15 patients treated (1) . A Cochrane review concluded that the H. pylori test-and-treat approach may be less expensive and just as effective as endoscopy-based management in younger patients (< 45 y) without alarm symptoms (2). Lara and colleagues showed similar efficacy of 1-day and standard 7-day treatment in achieving H. pylori eradication. Although dyspepsia symptoms improved, few patients had complete relief. If reproducible, a single-day course would likely have great advantages in cost, convenience, and adverse effects. However, the 95% eradication rate in this study was much higher than that of previous studies, with rates ranging from 20% to 83% (3).
We offer a few words of caution about this study. Most patients were > 45 years old and, under current guidelines, should have endoscopy to exclude cancer. Moreover, 1-day therapy may be insufficient to heal ulcers in the 10% to 15% subset of patients with dyspepsia and underlying peptic ulcer disease. An important question remains the symptom recurrence rate over time. Longer follow-up will be needed in future studies to address this.
The 1-day quadruple therapy, although intriguing, cannot be recommended based on current evidence. Until further studies are done with blinding to treatment allocation and longer follow-up, we recommend a minimum 7-day course of H. pylori treatment for patients with functional dyspepsia who choose the eradication option.
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